查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965896

創傷後壓力症候群治療市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、分銷管道、地區和競爭格局分類，2021-2031年

Post-traumatic Stress Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球創傷後壓力症候群 (PTSD) 治療市場預計將從 2025 年的 9.6939 億美元成長到 2031 年的 12.8063 億美元，預測期內複合年成長率為 4.75%。

治療方法通常採用藥物治療和心理治療相結合的方法，旨在緩解創傷經歷引發的過度警覺、逃避行為和侵入性思維等症狀。這個市場的主要驅動力是地緣政治衝突、自然災害和事故造成的創傷事件日益增多，以及診斷工具的進步使得早期療育可能。此外，政府加大對精神衛生基礎設施的投入，以及公眾對心理創傷長期影響的認知不斷提高，也有效地擴大了積極尋求專業幫助的患者群體。

市場概覽
預測期 2027-2031
市場規模：2025年 9.6939億美元
市場規模：2031年 1,280,630,000 美元
複合年成長率：2026-2031年 4.75%
成長最快的細分市場 抗憂鬱劑
最大的市場 北美洲

然而，合格的心理健康專業人員短缺以及專業治療的高昂費用阻礙了市場成長，限制了患者獲得持續治療的機會。鑑於該疾病的慢性特徵和長期管理的必要性，這種治療機會的不平等尤為嚴重。世界衛生組織（世衛組織）預測，到2024年，全球約有3.9%的人口在其一生中的某個階段會經歷創傷後壓力症候群（PTSD），這凸顯了有效治療方案在應對這一普遍存在的疾病負擔方面存在著巨大的未滿足需求。

市場促進因素

新型藥物和迷幻療法的快速發展正在從根本上改變全球創傷後壓力症候群（PTSD）治療市場，克服了傳統抗憂鬱症的限制。臨床開發平臺日益聚焦於迷幻劑輔助心理療法，尤其是使用MDMA和裸蓋菇素的療法，為對標準療法無效的患者提供了新的作用機制。這一趨勢正推動大量資本投資，以推動這些化合物從臨床試驗走向商業化。例如，2024年1月，Lycos Therapeutics公司在A輪資金籌措中籌集了超過1億美元，用於推進其MDMA輔助療法的研究階段。如此龐大的資金籌措反映了業界對下一代療法的信心，這些治療方法與傳統藥物干預相比，能夠提供更優的症狀緩解和功能恢復。

同時，對退伍軍人復健和軍人醫療保健支出的日益重視也在推動市場發展，因為世界各國政府都在優先考慮為軍人提供心理健康資源。軍人中較高的發病率要求為自殺預防和專門治療計畫提供充足的資金籌措，並確保對治療服務的穩定需求。 2024年3月，美國退伍軍人事務部申請在2025財政年度心理健康預算中撥款171億美元，以改善醫療保健服務的可近性和品質。這項財政承諾至關重要。正如科恩退伍軍人網路在2024年6月指出的那樣，大約7%的退伍軍人在其一生中的某個階段會患上這種疾病，而美國成年人口的這一比例為6%，這使得聯邦政府的此類支出成為持續採購醫療保健系統和解決方案的重要驅動力。

市場挑戰

全球創傷後壓力症候群（PTSD）治療市場擴張的一大障礙是合格心理健康專業的短缺。這種短缺造成了嚴重的瓶頸，使醫療保健系統無法充分滿足日益成長的創傷相關護理需求。當患者無法預約到合適的專家時，診斷率就會下降，必要的藥物和心理治療也會被延遲。因此，治療服務和藥物的使用量減少，儘管疾病的盛行率很高，但直接限制了相關人員的獲利能力。

這種供需失衡嚴重限制了患者持續治療的機會。根據美國心理學會預測，到2024年，約有53%的心理學家將表示沒有空餘名額接收新患者。如此嚴重的預約名額短缺迫使許多人放棄尋求專業協助，導致他們退出病患群體。這種對勞動力能力的結構性限制削弱了應對該疾病普遍負擔的努力，並減緩了市場的整體成長勢頭。

市場趨勢

將虛擬實境（VR）技術融入長期暴露療法，透過提供一個可控的身臨其境型創傷處理環境，正在革新迴避行為的管理方式。與傳統的想像暴露療法不同，VR平台允許臨床醫生重現創傷情境，並呈現特定的感官細節，從而幫助那些難以進行視覺想像的患者建立情感聯繫並逐漸適應。這項技術正在聯邦醫療保健系統中迅速擴展，以改善對軍人的治療服務。例如，2024年7月，美國退伍軍人事務部報告稱，已向170多家醫療中心部署了3500多台虛擬實境頭戴設備，以支持退伍軍人的康復和心理健康護理。

人工智慧驅動的數位療法和心理健康應用程式的興起，正在建立一種全新的、便利的、非侵入性的護理模式，作為傳統藥物療法的補充。這些數位介入措施利用複雜的演算法和神經回饋機制，幫助調節患者的生理壓力指標，為那些對傳統藥物療法無效的患者提供了有效的替代方案。 FDA批准的、能夠調節大腦活動的設備的商業性擴張，也印證了這一趨勢。據GrayMatters Health公司稱，其數位療法「Prism」於2024年10月進行的一項關鍵臨床試驗顯示，67%的參與者症狀得到了顯著改善。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：創傷後壓力症候群治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（抗憂鬱症、抗精神病藥、抗焦慮藥、其他）
    • 通路（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美創傷後壓力症候群治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲創傷後壓力症候群治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區創傷後壓力症候群治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲創傷後壓力症候群治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲創傷後壓力症候群治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球創傷後壓力症候群治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Lupin Limited
  • Pfizer Inc.
  • Aurobindo Pharma Limited
  • Merck KGaA
  • GlaxoSmithKline Plc
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
  • Jazz Pharmaceuticals Inc.
  • Bionomics Limited
  • Aptinyx Inc.
  • AstraZeneca Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20216

The Global Post-traumatic Stress Disorder Treatment Market is projected to expand from USD 969.39 Million in 2025 to USD 1280.63 Million by 2031, registering a CAGR of 4.75% during the forecast period. Treatment regimens typically combine pharmacotherapy and psychotherapeutic approaches designed to mitigate symptoms such as hyperarousal, avoidance behaviors, and intrusive thoughts caused by traumatic experiences. The market is largely sustained by the growing incidence of trauma resulting from geopolitical conflicts, natural disasters, and accidents, alongside advancements in diagnostic tools that allow for earlier intervention. Furthermore, increased government investment in mental health infrastructure and rising public awareness regarding the long-term effects of psychological trauma are effectively broadening the patient population actively seeking professional help.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 969.39 Million
Market Size 2031USD 1280.63 Million
CAGR 2026-20314.75%
Fastest Growing SegmentAntidepressants
Largest MarketNorth America

However, market growth is hindered by a scarcity of qualified mental health professionals and the high costs associated with specialized therapy, which restrict consistent patient access to care. This gap in accessibility is particularly critical given the chronic nature of the condition and the need for long-term management. According to the World Health Organization, approximately 3.9% of the global population in 2024 has experienced post-traumatic stress disorder at some point in their lives, highlighting a significant unmet need for effective therapeutic solutions to address this widespread burden.

Market Driver

The rapid advancement of novel pharmacotherapies and psychedelics is fundamentally transforming the global post-traumatic stress disorder treatment market by addressing the shortcomings of traditional antidepressants. Clinical pipelines are increasingly focusing on psychedelic-assisted psychotherapies, specifically using MDMA and psilocybin, which provide new mechanisms of action for patients resistant to standard treatments. This trend is attracting substantial capital investment to move these compounds from clinical trials to commercialization; for example, Lykos Therapeutics raised over $100 million in Series A funding in January 2024 to advance its investigational MDMA-assisted therapy. Such significant funding reflects the industry's confidence in these next-generation treatments to deliver better symptom remission and functional recovery than conventional pharmacologic interventions.

Simultaneously, the market is driven by a heightened focus on veteran rehabilitation and military healthcare spending, as governments prioritize mental health resources for service members. High prevalence rates among military personnel require robust funding for suicide prevention and specialized treatment programs, ensuring a steady demand for therapeutic services. In March 2024, the U.S. Department of Veterans Affairs requested $17.1 billion for its 2025 mental health budget to enhance access and quality of care. This financial commitment is crucial, as the Cohen Veterans Network noted in June 2024 that approximately 7% of veterans will experience the disorder in their lifetime, compared to 6% of the general U.S. adult population, making these federal expenditures a key catalyst for the consistent procurement of care systems and solutions.

Market Challenge

A primary obstacle to the expansion of the Global Post-traumatic Stress Disorder Treatment Market is the shortage of qualified mental health professionals. This workforce scarcity creates a critical bottleneck, preventing the healthcare system from adequately meeting the growing demand for trauma-related care. When patients struggle to secure timely appointments with specialists, diagnosis rates slow down, and the initiation of necessary pharmacotherapy or psychotherapy is delayed. As a result, the market sees reduced consumption of treatment services and medications, which directly limits revenue potential for industry stakeholders despite the high prevalence of the condition.

This imbalance between supply and demand significantly restricts patient access to consistent management. According to the American Psychological Association, roughly 53% of psychologists reported having no openings for new patients in 2024. This profound lack of availability compels many individuals to abandon their search for professional help, effectively removing them from the active patient pool. Such structural limitations in workforce capacity undermine efforts to address the widespread burden of the disorder, thereby slowing the overall growth trajectory of the market.

Market Trends

The incorporation of Virtual Reality into Prolonged Exposure Therapy is revolutionizing the management of avoidance behaviors by offering controlled, immersive environments for processing trauma. Unlike traditional imaginal exposure, virtual reality platforms allow clinicians to replicate traumatic scenarios with specific sensory details, facilitating emotional engagement and habituation in patients who find visualization difficult. This technology is being rapidly scaled within federal healthcare systems to improve therapeutic delivery for service members; for instance, the U.S. Department of Veterans Affairs reported in July 2024 that it had deployed over 3,500 virtual reality headsets across more than 170 medical centers to support veteran rehabilitation and mental health care.

The rise of AI-powered digital therapeutics and mental health apps is establishing a new paradigm of accessible, non-invasive care that serves as an adjunct to standard pharmacotherapy. These digital interventions employ advanced algorithms and neurofeedback mechanisms to help patients regulate physiological stress markers, offering a viable alternative for individuals resistant to conventional medication. This trend is illustrated by the commercial expansion of FDA-cleared devices designed to modulate brain activity; according to GrayMatters Health in October 2024, a pivotal clinical trial for its Prism digital therapeutic showed that 67% of participants achieved significant improvement in their symptoms.

Key Market Players

  • Lupin Limited
  • Pfizer Inc.
  • Aurobindo Pharma Limited
  • Merck KGaA
  • GlaxoSmithKline Plc
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
  • Jazz Pharmaceuticals Inc.
  • Bionomics Limited
  • Aptinyx Inc.
  • AstraZeneca Plc

Report Scope

In this report, the Global Post-traumatic Stress Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Post-traumatic Stress Disorder Treatment Market, By Drug Class

  • Antidepressants
  • Antipsychotics
  • Anti-anxiety
  • Others

Post-traumatic Stress Disorder Treatment Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Post-traumatic Stress Disorder Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Post-traumatic Stress Disorder Treatment Market.

Available Customizations:

Global Post-traumatic Stress Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Post-traumatic Stress Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Antidepressants, Antipsychotics, Anti-anxiety, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Post-traumatic Stress Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Post-traumatic Stress Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Post-traumatic Stress Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Post-traumatic Stress Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Post-traumatic Stress Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Post-traumatic Stress Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Post-traumatic Stress Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Post-traumatic Stress Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Post-traumatic Stress Disorder Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Post-traumatic Stress Disorder Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Post-traumatic Stress Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Post-traumatic Stress Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Post-traumatic Stress Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Post-traumatic Stress Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Post-traumatic Stress Disorder Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Post-traumatic Stress Disorder Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Post-traumatic Stress Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Post-traumatic Stress Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Post-traumatic Stress Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Post-traumatic Stress Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Post-traumatic Stress Disorder Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Post-traumatic Stress Disorder Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Post-traumatic Stress Disorder Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Post-traumatic Stress Disorder Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Post-traumatic Stress Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Lupin Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Aurobindo Pharma Limited
  • 15.4. Merck KGaA
  • 15.5. GlaxoSmithKline Plc
  • 15.6. Otsuka Pharmaceutical Development & Commercialization, Inc.
  • 15.7. Jazz Pharmaceuticals Inc.
  • 15.8. Bionomics Limited
  • 15.9. Aptinyx Inc.
  • 15.10. AstraZeneca Plc

16. Strategic Recommendations

17. About Us & Disclaimer